Michael advises clients on the tax aspects of domestic and cross-border transactions, including mergers and acquisitions, spinoffs, joint ventures, and debt and equity financings.
Cooley advised Alumis (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, on its definitive agreement with ACELYRIN to merge in an all-stock transaction.
